{TAIL ~ This invention} relates to aspartyl protease inhibitors, pharmaceutical compositions comprising said compounds, their use in the treatment of cardiovascular diseases, {HEAD ~ cognitive and neurodegenerative diseases}, and their use as inhibitors of the Human Immunodeficiency Virus, plasmepsins, cathepsin D and protozoal enzymes 
{ TAIL ~ This invention } relates to aspartyl protease inhibitors , pharmaceutical compositions comprising said compounds , their use in the treatment of cardiovascular diseases , { HEAD ~ cognitive and neurodegenerative diseases } , and their use as inhibitors of the Human Immunodeficiency Virus , plasmepsins , cathepsin D and protozoal enzymes
TAIL TAIL TAIL TAIL TAIL TAIL OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH HEAD HEAD HEAD HEAD HEAD HEAD HEAD HEAD OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH